DMD Celsis microsomes mean better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rotzinger, S.
Right arrow Articles by Baker, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rotzinger, S.
Right arrow Articles by Baker, G. B.

Vol. 26, Issue 6, 572-575, June 1998

Trazodone Is Metabolized to m-Chlorophenylpiperazine by CYP3A4 from Human Sources

Susan Rotzinger,1 Jian Fang, and Glen B. Baker

Neurochemical Research Unit, Department of Psychiatry and Faculty of Pharmacy and Pharmaceutical Sciences, and Division of Neuroscience, University of Alberta

The metabolism of the antidepressant drug trazodone to its active metabolite, m-chlorophenylpiperazine (mCPP), was studied in vitro using human liver microsomal preparations and cDNA-expressed human cytochrome P450 (P450) enzymes. The kinetics of mCPP formation from trazodone were determined, and three in vitro experiments were performed to identify the major P450 enzyme involved. Trazodone (100 µM) was incubated with 16 different human liver microsomal preparations characterized for activities of 7 different P450 isoforms. The production of mCPP correlated significantly with activity of cytochrome P4503A4 (CYP3A4) only. Trazodone (100 µM) was then incubated with microsomes from cells expressing human CYP1A1, CYP1A2, CYP2C8, CYP2C9arg, CYP2C9cys, CYP2C19, CYP2D6, or CYP3A4. Only incubations with CYP3A4 resulted in mCPP formation. In the third experiment, the CYP3A4 inhibitor ketoconazole was found to inhibit mCPP formation concentration dependently in both human liver microsomes and in microsomes from cells expressing human CYP3A4. The present results indicate that trazodone is a substrate for CYP3A4, that CYP3A4 is a major isoform involved in the production of mCPP from trazodone, and that there is the possibility of drug-drug interactions with trazodone and other substrates, inducers and/or inhibitors of CYP3A4.

1   This work is in partial fulfillment for the degree of Doctor of Philosophy.

Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
B. Wen, L. Ma, A. D. Rodrigues, and M. Zhu
Detection of Novel Reactive Metabolites of Trazodone: Evidence for CYP2D6-Mediated Bioactivation of m-Chlorophenylpiperazine
Drug Metab. Dispos., May 1, 2008; 36(5): 841 - 850.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
S. Williams, G. Wynn, K. Cozza, and N. B. Sandson
Cardiovascular Medications
Psychosomatics, December 1, 2007; 48(6): 537 - 547.
[Full Text] [PDF]

Home page
 APPI Online CMEHome page
References
PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2.
[Full Text]

Home page
 PsychosomaticsHome page
N. S. Karnik and J. R. Maldonado
Antidepressant and Statin Interactions: A Review and Case Report of Simvastatin and Nefazodone-Induced Rhabdomyolysis and Transaminitis
Psychosomatics, December 1, 2005; 46(6): 565 - 568.
[Full Text] [PDF]

Home page
 PsychosomaticsHome page
N. B. Sandson, S. C. Armstrong, and K. L. Cozza
An Overview of Psychotropic Drug-Drug Interactions
Psychosomatics, October 1, 2005; 46(5): 464 - 494.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
Y. Arima, C. Kubo, M. Tsujimoto, H. Ohtani, and Y. Sawada
Improvement of Dry Mouth by Replacing Paroxetine with Fluvoxamine
Ann. Pharmacother., March 1, 2005; 39(3): 567 - 571.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. S. Kalgutkar, S. Zhou, O. A. Fahmi, and T. J. Taylor
Influence of Lipophilicity on the Interactions of N-Alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and Their Positively Charged N-Alkyl-4-phenylpyridinium Metabolites with Cytochrome P450 2D6
Drug Metab. Dispos., May 1, 2003; 31(5): 596 - 605.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, S. M. Fogelman, G. Chen, J. A. Graf, P. Mertzanis, S. Byron, K. E. Culm, B. W. Granda, et al.
Short-Term Exposure to Low-Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone
J. Clin. Pharmacol., April 1, 2003; 43(4): 414 - 422.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. Venkatakrishnan, L. L. von Moltke, M. H. Court, J. S. Harmatz, C. L. Crespi, and D. J. Greenblatt
Comparison between Cytochrome P450 (CYP) Content and Relative Activity Approaches to Scaling from cDNA-Expressed CYPs to Human Liver Microsomes: Ratios of Accessory Proteins as Sources of Discrepancies between the Approaches
Drug Metab. Dispos., April 13, 2001; 28(12): 1493 - 1504.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.